Skip to main content
Erschienen in: Child's Nervous System 12/2016

04.10.2016 | Original Paper

Pediatric neurofibromatosis type 2: clinical and molecular presentation, management of vestibular schwannomas, and hearing rehabilitation

verfasst von: Nicolas -Xavier Bonne, Rabih Aboukais, Marc Baroncini, Audrey Hochart, Pierre Leblond, Franck Broly, Frédérique Dubrulle, Jean-Paul Lejeune, Christophe Vincent

Erschienen in: Child's Nervous System | Ausgabe 12/2016

Einloggen, um Zugang zu erhalten

Abstract

Objective

This study aims to describe the clinical and molecular presentation of pediatric neurofibromatosis type 2 (NF2) and the subsequent management of vestibular schwannomas (VS) and hearing rehabilitation.

Methods

This is a single-center retrospective study of neurofibromatosis type 2 diagnosed before the age of 18 years old from 1997. Natural history of vestibular schwannomas and surgical outcomes were evaluated using volumetric MRI, hearing, and facial nerve assessment. Patients included in chemotherapy protocols were excluded.

Results

From a database of 80 patients followed up for NF2 on a regular basis, 25 patients were eligible (11 sporadic cases, 14 inherited in five families). The mean age at diagnosis was 11.6 years old. The average clinical follow-up was 6.5 years. NF2 mutation was identified in 81 % of the probands. The average growth rate based on the maximum linear diameter (DGR) was 1.68 mm/year (n = 33, average follow-up 4.22 years) and 545 mm3/year in volumetric assessment (VGR) for VS larger than 1 cm (n = 21, average follow-up 3.4 years). In unoperated ears, hearing was stable in about 50 % of ears. The mean change in dB HL was 9.5 dB/year for pure-tone average and 3.5 for speech-recognition threshold (n = 34, 5.5 years 1–12). Eight children required removal through a translabyrinthine approach (mean follow-up was 4.5 years), six patients were operated on for hearing preservation (mean postoperative follow-up 4.3 years). Six patients were eligible for hearing rehabilitation with cochlear implantation (I), and five received placement of an auditory brainstem implant.

Conclusion

Early diagnosis and treatment of small growing VS should be carefully discussed considering familial history and possible rehabilitation with a CI.
Literatur
5.
Zurück zum Zitat Martuza RL, Ojemann RG (1982) Bilateral acoustic neuromas: clinical aspects, pathogenesis, and treatment. Neurosurgery 10:1–12CrossRefPubMed Martuza RL, Ojemann RG (1982) Bilateral acoustic neuromas: clinical aspects, pathogenesis, and treatment. Neurosurgery 10:1–12CrossRefPubMed
6.
Zurück zum Zitat Rouleau GA, Seizinger BR, Wertelecki W, et al. (1990) Flanking markers bracket the neurofibromatosis type 2 (NF2) gene on chromosome 22. Am J Hum Genet 46:323–328PubMedPubMedCentral Rouleau GA, Seizinger BR, Wertelecki W, et al. (1990) Flanking markers bracket the neurofibromatosis type 2 (NF2) gene on chromosome 22. Am J Hum Genet 46:323–328PubMedPubMedCentral
7.
Zurück zum Zitat Trofatter JA, MacCollin MM, Rutter JL, et al. (1993) A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 75:826CrossRefPubMed Trofatter JA, MacCollin MM, Rutter JL, et al. (1993) A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 75:826CrossRefPubMed
8.
Zurück zum Zitat Rouleau GA, Merel P, Lutchman M, et al. (1993) Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 363:515–521. doi:10.1038/363515a0 CrossRefPubMed Rouleau GA, Merel P, Lutchman M, et al. (1993) Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 363:515–521. doi:10.​1038/​363515a0 CrossRefPubMed
12.
Zurück zum Zitat Evans DGR, Ramsden RT, Shenton A, et al. (2007) Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification. J Med Genet 44:424–428. doi:10.1136/jmg.2006.047753 CrossRefPubMedPubMedCentral Evans DGR, Ramsden RT, Shenton A, et al. (2007) Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification. J Med Genet 44:424–428. doi:10.​1136/​jmg.​2006.​047753 CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Baser ME, Mautner VF, Ragge NK, et al. (1996) Presymptomatic diagnosis of neurofibromatosis 2 using linked genetic markers, neuroimaging, and ocular examinations. Neurology 47:1269–1277CrossRefPubMed Baser ME, Mautner VF, Ragge NK, et al. (1996) Presymptomatic diagnosis of neurofibromatosis 2 using linked genetic markers, neuroimaging, and ocular examinations. Neurology 47:1269–1277CrossRefPubMed
14.
Zurück zum Zitat Evans DG, Newton V, Neary W, et al. (2000) Use of MRI and audiological tests in presymptomatic diagnosis of type 2 neurofibromatosis (NF2. J Med Genet 37:944–947CrossRefPubMedPubMedCentral Evans DG, Newton V, Neary W, et al. (2000) Use of MRI and audiological tests in presymptomatic diagnosis of type 2 neurofibromatosis (NF2. J Med Genet 37:944–947CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Harsh GR, MacCollin M, McKenna MJ, et al. (1995) Molecular genetic screening for children at risk of neurofibromatosis 2. Arch Otolaryngol Head Neck Surg 121:590–591CrossRefPubMed Harsh GR, MacCollin M, McKenna MJ, et al. (1995) Molecular genetic screening for children at risk of neurofibromatosis 2. Arch Otolaryngol Head Neck Surg 121:590–591CrossRefPubMed
16.
17.
Zurück zum Zitat Piotrowski A, Xie J, Liu YF, et al. (2014) Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas. Nat Genet 46:182–187. doi:10.1038/ng.2855 CrossRefPubMed Piotrowski A, Xie J, Liu YF, et al. (2014) Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas. Nat Genet 46:182–187. doi:10.​1038/​ng.​2855 CrossRefPubMed
18.
Zurück zum Zitat Parry DM, Eldridge R, Kaiser-Kupfer MI, et al. (1994) Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet 52:450–461. doi:10.1002/ajmg.1320520411 CrossRefPubMed Parry DM, Eldridge R, Kaiser-Kupfer MI, et al. (1994) Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet 52:450–461. doi:10.​1002/​ajmg.​1320520411 CrossRefPubMed
19.
Zurück zum Zitat Mautner VF, Tatagiba M, Guthoff R, et al. (1993) Neurofibromatosis 2 in the pediatric age group. Neurosurgery 33:92–96CrossRefPubMed Mautner VF, Tatagiba M, Guthoff R, et al. (1993) Neurofibromatosis 2 in the pediatric age group. Neurosurgery 33:92–96CrossRefPubMed
20.
Zurück zum Zitat Ruggieri M, Iannetti P, Polizzi A, et al. (2005) Earliest clinical manifestations and natural history of neurofibromatosis type 2 (NF2) in childhood: a study of 24 patients. Neuropediatrics 36:21–34. doi:10.1055/s-2005-837581 CrossRefPubMed Ruggieri M, Iannetti P, Polizzi A, et al. (2005) Earliest clinical manifestations and natural history of neurofibromatosis type 2 (NF2) in childhood: a study of 24 patients. Neuropediatrics 36:21–34. doi:10.​1055/​s-2005-837581 CrossRefPubMed
24.
Zurück zum Zitat Cunningham CD, Friedman RA, Brackmann DE, et al. (2005) Neurotologic skull base surgery in pediatric patients. Otol Neurotol Off Publ Am Otol Soc Am Neurotol Soc Eur Acad Otol Neurotol 26:231–236CrossRef Cunningham CD, Friedman RA, Brackmann DE, et al. (2005) Neurotologic skull base surgery in pediatric patients. Otol Neurotol Off Publ Am Otol Soc Am Neurotol Soc Eur Acad Otol Neurotol 26:231–236CrossRef
26.
Zurück zum Zitat Niemczyk K, Dubrulle F, Vaneecloo FM, et al. (2002) Clinical implications of acoustic neuromas growth rate in volumetric study. Ann Oto-Laryngol Chir Cervico Faciale Bull Société Oto-Laryngol Hôpitaux Paris 119:259–263 Niemczyk K, Dubrulle F, Vaneecloo FM, et al. (2002) Clinical implications of acoustic neuromas growth rate in volumetric study. Ann Oto-Laryngol Chir Cervico Faciale Bull Société Oto-Laryngol Hôpitaux Paris 119:259–263
27.
Zurück zum Zitat Niemczyk K, Vaneecloo FM, Lemaitre L, et al. (1999) The growth of acoustic neuromas in volumetric radiologic assessment. Am J Otol 20:244–248PubMed Niemczyk K, Vaneecloo FM, Lemaitre L, et al. (1999) The growth of acoustic neuromas in volumetric radiologic assessment. Am J Otol 20:244–248PubMed
29.
Zurück zum Zitat Friedman RA, Goddard JC, Wilkinson EP, et al. (2011) Hearing preservation with the middle cranial fossa approach for neurofibromatosis type 2. Otol Neurotol Off Publ Am Otol Soc Am Neurotol Soc Eur Acad Otol Neurotol 32:1530–1537. doi:10.1097/MAO.0b013e3182355855 CrossRef Friedman RA, Goddard JC, Wilkinson EP, et al. (2011) Hearing preservation with the middle cranial fossa approach for neurofibromatosis type 2. Otol Neurotol Off Publ Am Otol Soc Am Neurotol Soc Eur Acad Otol Neurotol 32:1530–1537. doi:10.​1097/​MAO.​0b013e3182355855​ CrossRef
30.
Zurück zum Zitat Brackmann DE, Fayad JN, Slattery WH 3rd, et al. (2001) Early proactive management of vestibular schwannomas in neurofibromatosis type 2. Neurosurgery 49:274–280 discussion 280–283PubMed Brackmann DE, Fayad JN, Slattery WH 3rd, et al. (2001) Early proactive management of vestibular schwannomas in neurofibromatosis type 2. Neurosurgery 49:274–280 discussion 280–283PubMed
31.
Zurück zum Zitat Goddard JC, Schwartz MS, Friedman RA (2010) Fundal fluid as a predictor of hearing preservation in the middle cranial fossa approach for vestibular schwannoma. Otol Neurotol Off Publ Am Otol Soc Am Neurotol Soc Eur Acad Otol Neurotol 31:1128–1134. doi:10.1097/MAO.0b013e3181e8fc3f CrossRef Goddard JC, Schwartz MS, Friedman RA (2010) Fundal fluid as a predictor of hearing preservation in the middle cranial fossa approach for vestibular schwannoma. Otol Neurotol Off Publ Am Otol Soc Am Neurotol Soc Eur Acad Otol Neurotol 31:1128–1134. doi:10.​1097/​MAO.​0b013e3181e8fc3f​ CrossRef
32.
Zurück zum Zitat Vincent C, Bonne N-X, Guérin C, et al. (2012) Middle fossa approach for resection of vestibular schwannoma: impact of cochlear fossa extension and auditory monitoring on hearing preservation. Otol Neurotol Off Publ Am Otol Soc Am Neurotol Soc Eur Acad Otol Neurotol 33:849–852. doi:10.1097/MAO.0b013e318254ede3 CrossRef Vincent C, Bonne N-X, Guérin C, et al. (2012) Middle fossa approach for resection of vestibular schwannoma: impact of cochlear fossa extension and auditory monitoring on hearing preservation. Otol Neurotol Off Publ Am Otol Soc Am Neurotol Soc Eur Acad Otol Neurotol 33:849–852. doi:10.​1097/​MAO.​0b013e318254ede3​ CrossRef
33.
Zurück zum Zitat Slattery WH, Hoa M, Bonne N, et al. (2011) Middle fossa decompression for hearing preservation: a review of institutional results and indications. Otol Neurotol Off Publ Am Otol Soc Am Neurotol Soc Eur Acad Otol Neurotol 32:1017–1024. doi:10.1097/MAO.0b013e3182267eb7 CrossRef Slattery WH, Hoa M, Bonne N, et al. (2011) Middle fossa decompression for hearing preservation: a review of institutional results and indications. Otol Neurotol Off Publ Am Otol Soc Am Neurotol Soc Eur Acad Otol Neurotol 32:1017–1024. doi:10.​1097/​MAO.​0b013e3182267eb7​ CrossRef
34.
Zurück zum Zitat Tringali S, Ferber-Viart C, Fuchsmann C, et al. (2010) Hearing preservation in retrosigmoid approach of small vestibular schwannomas: prognostic value of the degree of internal auditory canal filling. Otol Neurotol Off Publ Am Otol Soc Am Neurotol Soc Eur Acad Otol Neurotol 31:1469–1472 Tringali S, Ferber-Viart C, Fuchsmann C, et al. (2010) Hearing preservation in retrosigmoid approach of small vestibular schwannomas: prognostic value of the degree of internal auditory canal filling. Otol Neurotol Off Publ Am Otol Soc Am Neurotol Soc Eur Acad Otol Neurotol 31:1469–1472
35.
Zurück zum Zitat Samii M (1995) Hearing preservation in bilateral acoustic neurinomas. Br J Neurosurg 9:413–424CrossRefPubMed Samii M (1995) Hearing preservation in bilateral acoustic neurinomas. Br J Neurosurg 9:413–424CrossRefPubMed
36.
Zurück zum Zitat Samii M, Matthies C, Tatagiba M (1997) Management of vestibular schwannomas (acoustic neuromas): auditory and facial nerve function after resection of 120 vestibular schwannomas in patients with neurofibromatosis 2. Neurosurgery 40:696–705 discussion 705–706CrossRefPubMed Samii M, Matthies C, Tatagiba M (1997) Management of vestibular schwannomas (acoustic neuromas): auditory and facial nerve function after resection of 120 vestibular schwannomas in patients with neurofibromatosis 2. Neurosurgery 40:696–705 discussion 705–706CrossRefPubMed
37.
40.
Zurück zum Zitat Tran Ba Huy P, Kania R, Frachet B, et al. (2009) Auditory rehabilitation with cochlear implantation in patients with neurofibromatosis type 2. Acta Otolaryngol (Stockh) 129:971–975. doi:10.1080/00016480802510202 CrossRef Tran Ba Huy P, Kania R, Frachet B, et al. (2009) Auditory rehabilitation with cochlear implantation in patients with neurofibromatosis type 2. Acta Otolaryngol (Stockh) 129:971–975. doi:10.​1080/​0001648080251020​2 CrossRef
41.
Zurück zum Zitat Vincenti V, Pasanisi E, Guida M, et al. (2008) Hearing rehabilitation in neurofibromatosis type 2 patients: cochlear versus auditory brainstem implantation. Audiol Neurootol 13:273–280. doi:10.1159/000115437 CrossRefPubMed Vincenti V, Pasanisi E, Guida M, et al. (2008) Hearing rehabilitation in neurofibromatosis type 2 patients: cochlear versus auditory brainstem implantation. Audiol Neurootol 13:273–280. doi:10.​1159/​000115437 CrossRefPubMed
43.
45.
Zurück zum Zitat Lustig LR, Yeagle J, Driscoll CLW, et al. (2006) Cochlear implantation in patients with neurofibromatosis type 2 and bilateral vestibular schwannoma. Otol Neurotol Off Publ Am Otol Soc Am Neurotol Soc Eur Acad Otol Neurotol 27:512–518. doi:10.1097/01.mao.0000217351.86925.51 Lustig LR, Yeagle J, Driscoll CLW, et al. (2006) Cochlear implantation in patients with neurofibromatosis type 2 and bilateral vestibular schwannoma. Otol Neurotol Off Publ Am Otol Soc Am Neurotol Soc Eur Acad Otol Neurotol 27:512–518. doi:10.​1097/​01.​mao.​0000217351.​86925.​51
46.
Zurück zum Zitat Vincent C, Zini C, Gandolfi A, et al. (2002) Results of the MXM Digisonic auditory brainstem implant clinical trials in Europe. Otol Neurotol Off Publ Am Otol Soc Am Neurotol Soc Eur Acad Otol Neurotol 23:56–60CrossRef Vincent C, Zini C, Gandolfi A, et al. (2002) Results of the MXM Digisonic auditory brainstem implant clinical trials in Europe. Otol Neurotol Off Publ Am Otol Soc Am Neurotol Soc Eur Acad Otol Neurotol 23:56–60CrossRef
47.
Zurück zum Zitat Colletti V, Shannon RV, Carner M, et al. (2010) Complications in auditory brainstem implant surgery in adults and children. Otol Neurotol Off Publ Am Otol Soc Am Neurotol Soc Eur Acad Otol Neurotol 31:558–564. doi:10.1097/MAO.0b013e3181db7055 Colletti V, Shannon RV, Carner M, et al. (2010) Complications in auditory brainstem implant surgery in adults and children. Otol Neurotol Off Publ Am Otol Soc Am Neurotol Soc Eur Acad Otol Neurotol 31:558–564. doi:10.​1097/​MAO.​0b013e3181db7055​
49.
Zurück zum Zitat Evans DGR (2009) Neurofibromatosis 2 [bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II]. Genet Med Off J Am Coll Med Genet 11:599–610. doi:10.1097/GIM.0b013e3181ac9a27 Evans DGR (2009) Neurofibromatosis 2 [bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II]. Genet Med Off J Am Coll Med Genet 11:599–610. doi:10.​1097/​GIM.​0b013e3181ac9a27​
51.
Zurück zum Zitat Hochart A, Gaillard V, Baroncini M, et al. (2015) Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2. J Neuro-Oncol 124:229–236. doi:10.1007/s11060-015-1828-8 CrossRef Hochart A, Gaillard V, Baroncini M, et al. (2015) Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2. J Neuro-Oncol 124:229–236. doi:10.​1007/​s11060-015-1828-8 CrossRef
53.
Zurück zum Zitat Karajannis MA, Legault G, Hagiwara M, et al. (2014) Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro-Oncol 16:292–297. doi:10.1093/neuonc/not150 CrossRefPubMed Karajannis MA, Legault G, Hagiwara M, et al. (2014) Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro-Oncol 16:292–297. doi:10.​1093/​neuonc/​not150 CrossRefPubMed
54.
Zurück zum Zitat Goutagny S, Raymond E, Esposito-Farese M, et al. (2015) Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas. J Neuro-Oncol 122:313–320. doi:10.1007/s11060-014-1710-0 CrossRef Goutagny S, Raymond E, Esposito-Farese M, et al. (2015) Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas. J Neuro-Oncol 122:313–320. doi:10.​1007/​s11060-014-1710-0 CrossRef
Metadaten
Titel
Pediatric neurofibromatosis type 2: clinical and molecular presentation, management of vestibular schwannomas, and hearing rehabilitation
verfasst von
Nicolas -Xavier Bonne
Rabih Aboukais
Marc Baroncini
Audrey Hochart
Pierre Leblond
Franck Broly
Frédérique Dubrulle
Jean-Paul Lejeune
Christophe Vincent
Publikationsdatum
04.10.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Child's Nervous System / Ausgabe 12/2016
Print ISSN: 0256-7040
Elektronische ISSN: 1433-0350
DOI
https://doi.org/10.1007/s00381-016-3257-1

Weitere Artikel der Ausgabe 12/2016

Child's Nervous System 12/2016 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.